Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce a four tonne order from UNAHCO, its largest purchase to date.
“UNAHCO has adopted and scaled an increasing use of our product, as is demonstrated by this record order and UNAHCO’s recent expansion of OxC-beta™ for use in poultry as well as swine,” said Kym Anthony, Avivagen’s CEO. “UNAHCO and their customers continue to see the benefits of using OxC-beta™ in their livestock feed, while our unique relationship with UNAHCO has served as a successful case study on how to test, adopt and scale as a business model with mutual benefit – for Avivagen and its customers – and we look forward to continuing to grow this important relationship.”
Avivagen is working diligently with its procurement partner on this order and is uncertain whether the entire order will be fulfilled and the related revenue included in its current fiscal quarter, ending October 31, 2020.
The Philippines continues to be an important and growing feed market for Avivagen, with an estimated annual feed production of 18.2 million metric tonnes for 2020, up dramatically from 11.75 million metric tonnes in 2016.i